BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27890931)

  • 1. A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells.
    Cheadle EJ; Lipowska-Bhalla G; Dovedi SJ; Fagnano E; Klein C; Honeychurch J; Illidge TM
    Leukemia; 2017 Jul; 31(7):1611-1621. PubMed ID: 27890931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
    Dovedi SJ; Melis MH; Wilkinson RW; Adlard AL; Stratford IJ; Honeychurch J; Illidge TM
    Blood; 2013 Jan; 121(2):251-9. PubMed ID: 23086756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.
    Palazzo A; Herter S; Grosmaire L; Jones R; Frey CR; Limani F; Bacac M; Umana P; Oldham RJ; Marshall MJE; Cox KL; Turaj AH; Cragg MS; Klein C; Carter MJ; Tannheimer S
    J Immunol; 2018 Apr; 200(7):2304-2312. PubMed ID: 29453281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody-dependent cytotoxicity and improves overall survival against CD20(+) rituximab-sensitive/-resistant Burkitt lymphoma (BL) and precursor B-acute lymphoblastic leukaemia (pre-B-ALL): potential targeted therapy in patients with poor risk CD20(+) BL and pre-B-ALL.
    Awasthi A; Ayello J; Van de Ven C; Elmacken M; Sabulski A; Barth MJ; Czuczman MS; Islam H; Klein C; Cairo MS
    Br J Haematol; 2015 Dec; 171(5):763-75. PubMed ID: 26471982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
    Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
    Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.
    Rosario M; Liu B; Kong L; Collins LI; Schneider SE; Chen X; Han K; Jeng EK; Rhode PR; Leong JW; Schappe T; Jewell BA; Keppel CR; Shah K; Hess B; Romee R; Piwnica-Worms DR; Cashen AF; Bartlett NL; Wong HC; Fehniger TA
    Clin Cancer Res; 2016 Feb; 22(3):596-608. PubMed ID: 26423796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
    Yasuhiro T; Sawada W; Klein C; Kozaki R; Hotta S; Yoshizawa T
    Leuk Lymphoma; 2017 Mar; 58(3):699-707. PubMed ID: 27684575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia.
    García-Muñoz R; Aguinaga L; Feliu J; Anton-Remirez J; Jorge-Del-Val L; Casajús-Navasal A; Nebot-Villacampa MJ; Daroca-Fernandez I; Domínguez-Garrido E; Rabasa P; Panizo C
    Immunotherapy; 2018 Mar; 10(6):491-499. PubMed ID: 29562857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of optimum vitamin D3 levels for NK cell-mediated rituximab- and obinutuzumab-dependent cellular cytotoxicity.
    Neumann F; Acker F; Schormann C; Pfreundschuh M; Bittenbring JT
    Cancer Immunol Immunother; 2018 Nov; 67(11):1709-1718. PubMed ID: 30132083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma.
    Herting F; Friess T; Bader S; Muth G; Hölzlwimmer G; Rieder N; Umana P; Klein C
    Leuk Lymphoma; 2014 Sep; 55(9):2151-5160. PubMed ID: 24304419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
    Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obinutuzumab in hematologic malignancies: lessons learned to date.
    Illidge T; Klein C; Sehn LH; Davies A; Salles G; Cartron G
    Cancer Treat Rev; 2015 Nov; 41(9):784-92. PubMed ID: 26190254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies.
    Tobinai K; Klein C; Oya N; Fingerle-Rowson G
    Adv Ther; 2017 Feb; 34(2):324-356. PubMed ID: 28004361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.
    García-Muñoz R; López-Díaz-de-Cerio A; Feliu J; Panizo A; Giraldo P; Rodríguez-Calvillo M; Grande C; Pena E; Olave M; Panizo C; Inogés S
    Immunol Res; 2016 Apr; 64(2):548-57. PubMed ID: 26659089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KIR/HLA interactions negatively affect rituximab- but not GA101 (obinutuzumab)-induced antibody-dependent cellular cytotoxicity.
    Terszowski G; Klein C; Stern M
    J Immunol; 2014 Jun; 192(12):5618-24. PubMed ID: 24795454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC).
    Khanna V; Kim H; Zhang W; Larson P; Shah M; Griffith TS; Ferguson D; Panyam J
    Sci Rep; 2021 Feb; 11(1):3346. PubMed ID: 33558639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model.
    Wang SY; Veeramani S; Racila E; Cagley J; Fritzinger DC; Vogel CW; St John W; Weiner GJ
    Blood; 2009 Dec; 114(26):5322-30. PubMed ID: 19805620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking NK cell inhibitory self-recognition promotes antibody-dependent cellular cytotoxicity in a model of anti-lymphoma therapy.
    Binyamin L; Alpaugh RK; Hughes TL; Lutz CT; Campbell KS; Weiner LM
    J Immunol; 2008 May; 180(9):6392-401. PubMed ID: 18424763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.